Literature DB >> 19366352

Post-conditioning restores pre-ischaemic receptor coupling in rat isolated hearts.

Rolf Schreckenberg1, Thorsten Maier, Klaus-Dieter Schlüter.   

Abstract

BACKGROUND AND
PURPOSE: Ischaemic preconditioning (IPC) and ischaemic post-conditioning (IPoC) activate signal transduction pathways that are also involved in receptor de- and re-sensitization such as phosphatidylinositol (PI) 3-kinase. Therefore, IPC and IPoC may affect post-infarct receptor coupling. EXPERIMENTAL APPROACH: Rat isolated hearts (Langendorff mode, constant flow) were exposed to 45 min flow arrest followed by 120 min reperfusion, including IPC or IPoC. Control hearts were perfused without a 45 min flow arrest. Left ventricular developed pressure (LVdevP) was determined. Thirty min after reperfusion, hearts were exposed to parathyroid hormone-related peptide (PTHrP) or isoprenaline for 10 min to monitor receptor responsiveness. Reperfusion injury was quantified by enzyme release. KEY
RESULTS: IPC and IPoC significantly reduced enzyme release compared with ischaemia and reperfusion alone by 75% and 62% respectively. Wortmannin or chelerythrine inhibiting either PI 3-kinase or protein kinase C, respectively, attenuated protection. Application of PTHrP 30 min after reperfusion did not change LVdevP in hearts exposed to ischaemia (+1 +/- 11%), but IPoC restored the normal and non-ischaemic response to PTHrP characterized by a negative inotropism (-8.3 +/- 3.9% and -12.9 +/- 6.1%). IPC restored a small negative inotropic effect (-4.4 +/- 4.7%). Application of a PTHrP receptor antagonist during the 45 min flow arrest attenuated receptor desensitization (DeltaLVdevP: -6.1 +/- 1.7%). Wortmannin but not chelerythrine attenuated the re-sensitizing effect of IPoC on post-ischaemic receptor coupling (DeltaLVdevP: +6.2 +/- 10.5 and -15.0 +/- 7.7%). As observed with PTHrP receptors, IPoC restored beta-adrenoceptors (DeltaLVdevP: +9.3 +/- 11.8% vs. 62.3 +/- 15.8%). CONCLUSIONS AND IMPLICATIONS: IPoC restores PTHrP receptor coupling in a PI 3-kinase-dependent way. A similar mechanism may allow beta-adrenoceptor re-sensitization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19366352      PMCID: PMC2697714          DOI: 10.1111/j.1476-5381.2008.00053.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  18 in total

1.  Bringing preconditioning and postconditioning into focus.

Authors:  David Garcia-Dorado; Jacob Vinten-Johansen; Hans Michael Piper
Journal:  Cardiovasc Res       Date:  2006-03-20       Impact factor: 10.787

2.  Trafficking of G protein-coupled receptors.

Authors:  Matthew T Drake; Sudha K Shenoy; Robert J Lefkowitz
Journal:  Circ Res       Date:  2006-09-15       Impact factor: 17.367

Review 3.  Reperfusion injury: does it exist?

Authors:  Garrett J Gross; John A Auchampach
Journal:  J Mol Cell Cardiol       Date:  2006-10-27       Impact factor: 5.000

4.  Vasodilatory effect of tuberoinfundibular peptide (TIP39): requirement of receptor desensitization and its beneficial effect in the post-ischemic heart.

Authors:  Günter Ross; Marcus P Heinemann; Klaus-Dieter Schlüter
Journal:  Peptides       Date:  2006-12-20       Impact factor: 3.750

5.  Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade.

Authors:  Sebastian Philipp; Xi-Ming Yang; Lin Cui; Amanda M Davis; James M Downey; Michael V Cohen
Journal:  Cardiovasc Res       Date:  2006-02-23       Impact factor: 10.787

6.  Sustained benefit 20 years after reperfusion therapy in acute myocardial infarction.

Authors:  Ron T van Domburg; Karel Sonnenschein; Robby Nieuwlaat; Otto Kamp; Corstiaan J Storm; Jeroen J Bax; Maarten L Simoons
Journal:  J Am Coll Cardiol       Date:  2005-07-05       Impact factor: 24.094

7.  Attenuated cardioprotection by ischemic preconditioning in coronary stenosed heart and its restoration by carvedilol.

Authors:  Kenichi Watanabe; Hiroyuki Yaoita; Kazuei Ogawa; Masayoshi Oikawa; Kazuhira Maehara; Yukio Maruyama
Journal:  Cardiovasc Res       Date:  2006-05-10       Impact factor: 10.787

8.  Cardiac-specific effects of parathyroid hormone-related peptide: modification by aging and hypertension.

Authors:  Günter Ross; Klaus-Dieter Schlüter
Journal:  Cardiovasc Res       Date:  2005-05-01       Impact factor: 10.787

Review 9.  Survival kinases in ischemic preconditioning and postconditioning.

Authors:  Derek J Hausenloy; Derek M Yellon
Journal:  Cardiovasc Res       Date:  2006-03-20       Impact factor: 10.787

10.  Prevention of the oxygen paradox in hypoxic-reoxygenated hearts.

Authors:  K D Schlüter; P Schwartz; B Siegmund; H M Piper
Journal:  Am J Physiol       Date:  1991-08
View more
  5 in total

1.  Modulation of receptor sensitivity: possible therapeutic target?

Authors:  Michel V Cohen; James M Downey
Journal:  Br J Pharmacol       Date:  2009-03       Impact factor: 8.739

2.  Specific Mechanisms Underlying Right Heart Failure: The Missing Upregulation of Superoxide Dismutase-2 and Its Decisive Role in Antioxidative Defense.

Authors:  Rolf Schreckenberg; Manuel Rebelo; Alexander Deten; Martin Weber; Susanne Rohrbach; Márton Pipicz; Csaba Csonka; Péter Ferdinandy; Rainer Schulz; Klaus-Dieter Schlüter
Journal:  Antioxid Redox Signal       Date:  2015-06-18       Impact factor: 8.401

3.  Adverse Effects on β-Adrenergic Receptor Coupling: Ischemic Postconditioning Failed to Preserve Long-Term Cardiac Function.

Authors:  Rolf Schreckenberg; Péter Bencsik; Martin Weber; Yaser Abdallah; Csaba Csonka; Kamilla Gömöri; Krisztina Kiss; János Pálóczi; Judit Pipis; Márta Sárközy; Péter Ferdinandy; Rainer Schulz; Klaus-Dieter Schlüter
Journal:  J Am Heart Assoc       Date:  2017-12-22       Impact factor: 5.501

4.  Autocrine effects of PCSK9 on cardiomyocytes.

Authors:  Annemarie Wolf; Hanna Sarah Kutsche; Rolf Schreckenberg; Martin Weber; Ling Li; Susanne Rohrbach; Rainer Schulz; Klaus-Dieter Schlüter
Journal:  Basic Res Cardiol       Date:  2020-11-10       Impact factor: 17.165

5.  Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo.

Authors:  Rolf Schreckenberg; Annemarie Wolf; Tamara Szabados; Kamilla Gömöri; István Adorján Szabó; Gergely Ágoston; Gábor Brenner; Péter Bencsik; Péter Ferdinandy; Rainer Schulz; Klaus-Dieter Schlüter
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.